Abstract: Methods for treating, reducing or reversing a motor deficit in a subject after a stroke comprising administering continuous electrical stimulation to the mesencephalic locomotor region (MLR) of the subject under sufficient conditions so as to treat, reduce or reverse the motor deficit of the subject are provided.

Abstract: The invention relates to chimeric antigen receptors (CAR) with a humanized targeting domain specific to the antigen ROR1. The invention encompasses the polynucleotides, vectors encoding said CARs and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy.

Abstract: A gradient system characterization function (e.g., a gradient system transfer function) may be developed by measuring a behavior of the MR device at a target temperature and developing at least one gradient system characterization function for a gradient coil of a magnetic resonance (MR) device at the target temperature based on the measured behavior. A patient may be subsequently imaged by the MR device, wherein the imaging process comprises measuring a temperature of a gradient coil, determining a gradient system characterization function at the measured temperature, calculating a pre-emphasized gradient of the gradient coil, and imaging the patient using the pre-emphasized magnetic field component.

Abstract: The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “?” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.

Abstract: A soluble polypeptide comprising a modified glycoprotein V (GPV) lacking a functional transmembrane domain for use in the treatment or prevention of a thrombotic disease in a subject, said treatment or prevention comprising administering to the subject an effective amount of said soluble polypeptide.

Abstract: The present invention relates to a device for the photocatalytic reduction of a substance with a structured reaction plate and/or a structured housing, wherein the reaction plate has, at least in some regions, a surface which contains a material with negative electron affinity and which can be electronically excited with radiation having a wavelength of ?180 nm.

Abstract: A calculating unit for calculating a recording trajectory of a CT system has a receive interface, an optimizer and a control unit. The receive interface serves for receiving measurement and simulation data relative to the object to be recorded. The optimizer is configured to determine the recording trajectory based on known degrees of freedom of the CT system, based on the measurement and simulation data and based on a test task from a group having a plurality of test tasks. The control unit is configured to output data in correspondence with the recording trajectory for controlling the CT system.

Abstract: A system for generating a traveling field free line, traveling along a propagation direction different from the orientation of said traveling field free line, said system comprising at least a first and a second coil assembly, wherein said first coil assembly is configured for generating a first stationary field free line at a first location when a current is flowing in the first coil assembly and the second coil assembly is current free, and wherein said second coil assembly is configured for generating a second stationary field free line at a second location, when a current is flowing in the second coil assembly and the first coil assembly is current free. The system further comprises a controller configured for driving the first and second coil assemblies with corresponding driving currents synchronized with each other, such that said traveling field free line travels along the propagation direction from a first location towards a second location.

Abstract: The present invention is directed to compounds of the general formula (I) and salts thereof wherein X? is halide, pseudohalide, sulphate, benzoate, acetate, trifluoroacetate, hydroxide, saccharinate or capsaicinate; R10 is hydrogen or C1-C10-alkyl; and R1-R9 independently are hydrogen, halogen, C1-C5-alkyl, C1-C4-alkoxy, C1-C20-alkoxycarbonyl. The invention is furthermore directed to a method for the preparation of these compounds. The compounds can be used as bitter substances in medicine, pharmaceutics and/or diagnostics. They can furthermore be used for the coupling to proteins and peptides by means of forming a peptide bond between the amino-group of the compounds of the present invention and a carboxyl-group of the protein or peptide.

Abstract: The present invention relates to a new class of sucrose esters and a method for their preparation.

Abstract: The present invention relates to a method for combined administration of carbon monoxide (CO) to an ex-vivo fluid and monitoring of the carbon monoxide administration, said method comprising: (i) generating CO by reacting a CO releasing molecule (CORM) with a release triggering molecule; (ii) administering CO to an ex-vivo fluid by contacting the ex-vivo fluid with the CO generated in step (i) via a gas-permeable membrane; (iii) analyzing carbon monoxide and/or a carbon monoxide marker after administering in step (ii) CO to the ex-vivo fluid by complementary monitoring techniques; (iv) adjusting the CO administration based on the analysis of the carbon monoxide or the carbon monoxide marker carried out in step (iii), if necessary. It furthermore relates to an extracorporeal circuit system for use in the method of the invention.

Abstract: The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.

Abstract: The present invention relates to a monolithic multi-layered material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a monolithic medical material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a process for the production of a multi-layered material having anisotropic pores. It further relates to a multi-layered material which can be produced by the process according to the invention.

Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Abstract: The present invention relates to a monolithic multi-layered material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a monolithic medical material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a process for the production of a multi-layered material having anisotropic pores. It further relates to a multi-layered material which can be produced by the process according to the invention.

Abstract: A compound contains a chemical dexpanthenol bound to a saccharide. A corresponding compound for use in therapeutic and/or cosmetic methods is also provided. The compound may be a skincare compound or a compound configured to be used in prophylaxis of skin diseases and/or treatment of skin diseases or a compound configured to be used as a medicament for accelerating wound healing.

Abstract: The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “?” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.

Abstract: The subject matter of the invention is a diagnostic sensor that can be formulated into a diagnostic chewing gum that detects relevant concentrations of influenza viruses in the oral cavity. The technical application is the initial diagnosis by those affected themselves, e.g. sore throats manifesting in them. By the detection of the influenza viruses a selective therapy of the infection is possible and employment of antibiotics that only are effective with bacterial diseases can be reduced.

Abstract: It is an object of the present invention to introduce carboxylic acid-functionalities suitable for coupling into the denatonium structure by means of simple synthesis, namely the synthesis of bitter principle derivatives based on the denatonium structure according to formula 1: For example, according to the invention, lidocaine derivatives may be reacted with carboxylated benzyl halogenides. The carboxylated denatonium derivatives of the present invention are especially applied in medicine, biology, medical engineering as well as cosmetics, the pharmaceutical, chemical, and foodstuff industry.

Abstract: The present invention relates to the biomarkers for predicting the clinical response to anti-LPS immunoglobulin treatments in patients in need thereof. In particular, the invention provides methods for predicting the clinical response to an anti-LPS immunoglobulin treatment in a patient in need thereof, said method comprising the steps of evaluating the expression of a predictive biomarker selected from the group consisting of CD14, CD68, TLR4, TLR7, IL6, IL8, IL10, IFN-alpha, IGF1, CXCL1, CXCL9, CXCL10, RAGE, GDNF, BCHE, and combination thereof, in said patient.